 Immunotherapy administered during recovery from chemotherapy may have tremendous advantages, as adoptive cellular therapy following lymphodepletive conditioning regimens has emerged as the most effective treatment strategy for advanced and refractory melanoma. Our hypothesis is that DC ex vivo expanded Autologous Lymphocyte Transfer xALT therapy targeting recurrent MBPNETs during recovery from myeloablative chemotherapy will be safe and will prolong survival in children and young adults with recurrent MBPNETs. 